David Gandara, MD

Articles by David Gandara, MD

KRAS G12C as a Predictor of Immunotherapy Benefit in EMPOWER-Lung 1

September 21st 2026

David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.

Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer

ByDavid Gandara, MD

August 6th 2014

David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.

Latest Updated Articles

Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer
August 6th 2014

David Gandara, MD

Articles by David Gandara, MD

KRAS G12C as a Predictor of Immunotherapy Benefit in EMPOWER-Lung 1

Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

DiBardino Outlines Phase 2 CONVERGE Trial Design of Radioenhancer in NSCLC

A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC

FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer

FDA Launches Expedited IND Pilot to Speed First-in-Human Trials

Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up